Douglas Lind

Douglas Lind

Plus aucun poste en cours
66 ans
Health Technology
Finance
Consumer Services

Profil

Douglas D.
Lind
is currently Chief Executive Officer at Apik Bio LLC since 2026.
Dr. Lind is also Co-President & Director at TMune Therapeutics, Inc., Director at HyperMed Imaging, Inc., and Director at Lentigen Technology, Inc. Former roles include Director at Viragen, Inc., MabVax Therapeutics, Inc., Opus Bio, Inc., Strand Life Sciences Pvt Ltd., Spectral Image, Inc., Flexible Stenting Solutions, Inc., and Enveric Biosciences, Inc. Dr. Lind was Managing Director at Burrill LLC from 2012 to 2013, Managing Director at GBP Capital, Managing Director at Biomark Capital Management Co. LLC from 2006 to 2025, Analyst at Morgan Stanley & Co. LLC in 2002, and Research Analyst at PaineWebber, Inc. in 1996.
Education includes graduate studies at the University of Iowa.

Postes actifs de Douglas Lind

SociétésPosteDébut
President -
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -

Anciens postes connus de Douglas Lind

SociétésPosteFin
Private Equity Investor 01/01/2025
Private Equity Investor 31/10/2013
Directeur/Membre du Conseil 01/02/2005
Analyst-Equity 24/01/2002
Corporate Officer/Principal 31/12/1996
Voir l'expérience en détail de Douglas Lind

Formation de Douglas Lind

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

92

Relations au 1er degré

16

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées16

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Commercial Services

Technology Services

Finance

Health Technology

Health Services

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Douglas Lind
🔇